SOURCE: Corporate Profile LLC

Corporate Profile LLC

February 11, 2011 08:00 ET

NeoStem CEO Dr. Robin Smith Interviewed on CorporateProfile.com

NEW YORK, NY--(Marketwire - February 11, 2011) - Corporate Profile, LLC announced today that NeoStem, Inc. (NYSE Amex: NBS) CEO, Dr. Robin Smith, was interviewed on CorporateProfile.com.

The video can be viewed at: www.corporateprofile.com.

NeoStem, Inc. is an international biopharmaceutical company with adult stem cell operations in the U.S., a network of adult stem cell therapeutic providers in China as well as a 51% ownership interest in a profitable Chinese generic pharmaceutical manufacturing company. NeoStem is focused on accelerating the development of proprietary cellular therapies and becoming a single source for collection, storage, manufacturing, therapeutic development and transportation of cells for cell based medicine and regenerative science globally. The Company also has licensed various cellular therapy technologies, including worldwide exclusive licenses to a wound healing technology and to VSEL™ Technology which uses very small embryonic-like stem cells, which are adult stem cells that have been shown to have several physical characteristics that are generally found in embryonic stem cells, and a T-cell regulatory technology through the acquisition of Progenitor Cell Therapy, LLC.

For more information, please visit: http://www.neostem.com

About Corporate Profile.com

CorporateProfile.com is a broadcasting website where Fashion meets Finance. Merging two mainstream industries results in a unique platform for investors to receive today's hottest tips and market info.

Safe Harbor Disclaimer

Under The Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectation.